Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Inventory (2018 - 2025)

Coherus Oncology (CHRS) has disclosed Inventory for 8 consecutive years, with $3.2 million as the latest value for Q4 2025.

  • Quarterly Inventory fell 24.6% to $3.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Dec 2025, down 24.6% year-over-year, with the annual reading at $3.2 million for FY2025, 24.6% down from the prior year.
  • Inventory hit $3.2 million in Q4 2025 for Coherus Oncology, up from $2.0 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $66.8 million in Q3 2023 to a low of $2.0 million in Q3 2025.
  • Historically, Inventory has averaged $36.7 million across 5 years, with a median of $38.2 million in 2021.
  • Biggest five-year swings in Inventory: surged 214.02% in 2021 and later crashed 95.7% in 2025.
  • Year by year, Inventory stood at $37.6 million in 2021, then rose by 3.05% to $38.8 million in 2022, then surged by 61.39% to $62.6 million in 2023, then crashed by 93.28% to $4.2 million in 2024, then fell by 24.6% to $3.2 million in 2025.
  • Business Quant data shows Inventory for CHRS at $3.2 million in Q4 2025, $2.0 million in Q3 2025, and $4.5 million in Q2 2025.